Nano drug aims to boost appetite and weight in pancreatic cancer patients
NCT ID NCT07408505
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new nano-formulation of megestrol acetate, a drug used to stimulate appetite and promote weight gain, in patients with advanced pancreatic cancer who suffer from anorexia-cachexia syndrome. The trial will enroll 56 patients and compare those receiving the nano-drug alongside standard chemotherapy to those receiving chemotherapy alone. The goal is to see if the nano-drug helps patients gain more than 5% of their body weight and improves their appetite and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nano-crystalline megestrol acetate
What this could lead to
If it works, this could provide a better-tolerated way to help advanced pancreatic cancer patients gain weight and improve their appetite and quality of life during chemotherapy.
What could go wrong
This is a small, early-phase study with only 56 participants, so results may not apply to all patients. The drug may not significantly improve outcomes, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinan, Shandong 0531
RECRUITINGJinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••